Lipid lowering drugs and the risk of recurrent venous thromboembolism

Abstract Introduction Several studies have suggested that statins may lower the risk of venous thromboembolism (VTE), whereas fibrates may increase this risk. However, no studies have evaluated whether lipid-lowering drugs (LLD) use was associated with the risk of VTE recurrence. Materials and metho...

Full description

Saved in:
Bibliographic Details
Published in:Thrombosis research 2012-12, Vol.130 (6), p.859-863
Main Authors: Delluc, Aurélien, Tromeur, Cécile, Le Moigne, Emmanuelle, Nowak, Emmanuel, Mottier, Dominique, Le Gal, Grégoire, Lacut, Karine
Format: Article
Language:English
Subjects:
Aged
Anticoagulants - administration & dosage
Biological and medical sciences
Blood and lymphatic vessels
Cardiology. Vascular system
Cohort Studies
Coronary heart disease
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
Female
Fibric Acids - therapeutic use
Heart
Hematology, Oncology and Palliative Medicine
Human health and pathology
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hypolipidemic Agents - therapeutic use
Life Sciences
Lipid lowering drugs
Male
Medical sciences
Middle Aged
Proportional Hazards Models
Prospective Studies
Recurrent venous thrombosis
Risk Factors
Secondary Prevention
Thrombosis risk factors
Venous Thromboembolism - drug therapy
Venous Thromboembolism - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Introduction Several studies have suggested that statins may lower the risk of venous thromboembolism (VTE), whereas fibrates may increase this risk. However, no studies have evaluated whether lipid-lowering drugs (LLD) use was associated with the risk of VTE recurrence. Materials and methods In a prospective cohort study, we followed-up all patients who had been treated for a first unprovoked VTE event in our centre. The association between LLD exposure and risk of recurrence of VTE after discontinuation of anticoagulation was analyzed with Cox proportional hazards model with adjustment for age, sex, body mass index, site of thrombosis, antiplatelets use, and duration of anticoagulation before inclusion in the study. Results 432 patients (median age 65.5 years interquartile range 45.0-75.0, 174 men) were followed up for a median of 29.5 months after discontinuation of anticoagulation. Sixty patients (13.9%) had recurrent VTE. During follow-up, 48 patients (11.1%) received statins, 36 patients (8.3%) received fibrates. In multivariate analysis, the risk of recurrent VTE associated with statin exposure was 1.02 (95% confidence interval 0.36-2.91) and 2.15 (95% confidence interval 1.01-4.61) for fibrate exposure. Conclusion Our results suggest an association between fibrate intake and an increased risk of recurrent VTE, whereas statin intake was not associated with recurrent VTE. Larger studies are needed to validate these results.
ISSN:0049-3848
1879-2472
DOI:10.1016/j.thromres.2012.08.296